Dr Agarwals Eye Hospital Shares to Trade on NSE

Dr Agarwals Eye Hospital Limited's shares have been admitted for trading on the National Stock Exchange (NSE) under the symbol DRAGARWQ, effective April 20, 2026. This exchange-led admission is expected to enhance stock liquidity and investor access for the Chennai-based eye care chain.

NSE Listing Details

The shares will trade on the NSE under the symbol DRAGARWQ. Crucially, this admission is an exchange-initiated move by the NSE itself. The company has not filed a formal listing application or entered into a Listing Agreement for this listing. The shares will now trade on the NSE in addition to their existing listing on the BSE.

Market Impact: Enhanced Liquidity and Access

Trading on the NSE is anticipated to significantly boost the liquidity of Dr Agarwals Eye Hospital's stock. This move could attract a broader investor base and improve price discovery, making the company's equity more accessible.

Company Background

Founded in 1957, Dr Agarwals Eye Hospital is one of India's oldest and most recognized eye care networks. The chain operates over 180 centers in India and more than 15 abroad. In recent corporate activity, the company's parent, Dr Agarwals Health Care Limited, completed its IPO in early 2025. A subsequent merger scheme was proposed for Dr. Agarwal's Eye Hospital Limited to merge into Dr Agarwals Health Care Limited. The company is already listed on the BSE under symbol 526783. As of December 31, 2025, its trailing 12-month revenue was approximately $51.3 million.

Impact for Shareholders

Shareholders can now trade Dr Agarwals Eye Hospital shares on both the BSE and NSE. This dual listing is expected to increase trading volumes and boost the stock's market visibility. Investors gain more trading avenues and potentially better trade execution.

Potential Risks

A primary risk is that the NSE listing is exchange-led without a formal company application. This could indicate potential execution challenges or an incomplete commitment to a formal listing process. The company has a history of regulatory issues, including SEBI imposing restrictions in 2013 for failing to meet minimum public shareholding norms. These were later resolved, but point to past challenges with compliance.

Competitive Landscape

Dr Agarwals Eye Hospital operates in a competitive market with other listed players such as Centre for Sight, ASG Eye Hospitals, Vasan Eye Care, Narayana Nethralaya, and Aravind Eye Hospital.

Key Metrics

• Trailing 12-month Revenue: $51.3 million (as of Dec 31, 2025)
• Network Facilities: 209 (as of Sep 30, 2024)

What to Watch For

Investors should monitor for official statements from Dr Agarwals Eye Hospital regarding its plans for a formal NSE listing. Tracking trading volumes and price movements for DRAGARWQ on the NSE will be key to gauging market reaction. Future corporate actions and financial performance, particularly post-amalgamation plans, will also be important indicators.